Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma: a Phase II Trial of the AIO (The RAP-Trial)

NCT03966118 is registered in ClinicalTrials.gov with P. C. Thuss-Patience as lead sponsor.

NCT NCT03966118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03966118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma: a Phase II Trial of the AIO (The RAP-Trial)
Lead sponsor
P. C. Thuss-Patience
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2019
Completion date
September 30, 2023
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the stomach, gastroesophageal junction adenocarcinoma